AR086852A1 - Compuestos de 1,1-dioxido de [1,2,4]tiadiazina para reducir el acido urico serico - Google Patents
Compuestos de 1,1-dioxido de [1,2,4]tiadiazina para reducir el acido urico sericoInfo
- Publication number
- AR086852A1 AR086852A1 ARP120102014A ARP120102014A AR086852A1 AR 086852 A1 AR086852 A1 AR 086852A1 AR P120102014 A ARP120102014 A AR P120102014A AR P120102014 A ARP120102014 A AR P120102014A AR 086852 A1 AR086852 A1 AR 086852A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- uric acid
- patient
- formula
- tiadiazine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente describe compuestos de 1,1-dióxido de [1,2,4]tiadiazina y sus sales farmacéuticamente aceptables, que son de utilidad para la reducción de ácido úrico sérico en un paciente que lo necesita que comprende la administración al paciente de una cantidad terapéutica o preventivamente efectiva de un compuesto de 1,1-dióxido de [1,2,4]tiadiazina.Reivindicación 1: Un método para reducir ácido úrico sérico en un paciente que comprende la administración al paciente de una cantidad terapéuticamente efectiva de un compuesto de la fórmula (1) en donde el anillo B es un resto de fórmula (2) ó (3); A es el resto de fórmula (4) ó (5); Z es -(CR11R12)n-; Y es -(CR13R14)m-; n es 1 ó 2; m es 2 ó 3; R1 es H, -NH2 o -(CH2)q-NH-S(O)2CH3, en donde q es 0 ó 1; R2 es alquilo C1-6, cicloalquilo C3-6, arilo o -(CH2)-R15, en donde R15 es un resto de fórmula (6), en donde R16, R17, R18, R19 y R20 son, de modo independiente, H, alquilo C1-6, hidroxi o halo; R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 y R14 son, de modo independiente, H o alquilo C1-6; en donde cada alquilo, cicloalquilo o arilo están opcionalmente sustituidos con uno o varios alquilo, hidroxilo o sustituyentes de halo; o una de sus sales, hidratos, solvatos, tautómeros o estereoisómeros terapéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161494288P | 2011-06-07 | 2011-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086852A1 true AR086852A1 (es) | 2014-01-29 |
Family
ID=47293671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102014A AR086852A1 (es) | 2011-06-07 | 2012-06-07 | Compuestos de 1,1-dioxido de [1,2,4]tiadiazina para reducir el acido urico serico |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8815847B2 (es) |
| EP (1) | EP2718273A4 (es) |
| JP (1) | JP6010614B2 (es) |
| KR (1) | KR20140037193A (es) |
| CN (1) | CN103827100B (es) |
| AR (1) | AR086852A1 (es) |
| AU (1) | AU2012268119B2 (es) |
| BR (1) | BR112013031484A2 (es) |
| CA (1) | CA2838257A1 (es) |
| EA (1) | EA023336B1 (es) |
| HK (1) | HK1197245A1 (es) |
| IL (1) | IL229701A0 (es) |
| MX (1) | MX2013014240A (es) |
| MY (1) | MY183704A (es) |
| SG (1) | SG195288A1 (es) |
| WO (1) | WO2012170536A1 (es) |
| ZA (1) | ZA201309706B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2908244C (en) * | 2013-03-25 | 2021-04-20 | United Therapeutics Corporation | Process of making prostacyclin compounds with linker thiol and pegylated forms |
| CN111233768B (zh) * | 2020-03-18 | 2021-08-03 | 徐州圣元化工有限公司 | 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3969518A (en) * | 1972-05-24 | 1976-07-13 | Merck & Co., Inc. | Inhibiting xanthine oxidase with 3-haloalkyl substituted benzothiadiazine-1,1-dioxides |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| DE60335564D1 (de) * | 2002-11-01 | 2011-02-10 | Abbott Lab | Antiinfektiöse mittel |
| BRPI0713684A2 (pt) | 2006-06-22 | 2012-10-30 | Anadys Pharmaceuticals Inc | compostos, composição farmaceuticamente aceitável e métodos de inibição da replicação de vìrus da hepatite c, de tratamento de célula e de tratamento ou prevenção da infecção do vìrus da hepatite c em maìfero carecido do mesmo |
| US7662958B2 (en) | 2006-07-19 | 2010-02-16 | Rolf Wagner | Anti-infective agents |
| UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
| WO2008147601A1 (en) * | 2007-04-17 | 2008-12-04 | University Of Florida Research Foundation, Inc. | Methods and compositions for ameliorating thiazide induced hyperlipidemia |
| CN102316871B (zh) * | 2008-06-10 | 2014-06-04 | 安那迪斯药品股份有限公司 | [1，2，4]噻二嗪1，1-二氧化合物 |
-
2012
- 2012-06-06 MY MYPI2013702371A patent/MY183704A/en unknown
- 2012-06-06 EA EA201391827A patent/EA023336B1/ru not_active IP Right Cessation
- 2012-06-06 MX MX2013014240A patent/MX2013014240A/es unknown
- 2012-06-06 BR BR112013031484A patent/BR112013031484A2/pt not_active IP Right Cessation
- 2012-06-06 JP JP2014514591A patent/JP6010614B2/ja not_active Expired - Fee Related
- 2012-06-06 SG SG2013089545A patent/SG195288A1/en unknown
- 2012-06-06 US US13/490,046 patent/US8815847B2/en not_active Expired - Fee Related
- 2012-06-06 AU AU2012268119A patent/AU2012268119B2/en not_active Expired - Fee Related
- 2012-06-06 WO PCT/US2012/041106 patent/WO2012170536A1/en active Application Filing
- 2012-06-06 KR KR1020147000309A patent/KR20140037193A/ko not_active Application Discontinuation
- 2012-06-06 EP EP12797573.8A patent/EP2718273A4/en not_active Withdrawn
- 2012-06-06 CN CN201280037547.8A patent/CN103827100B/zh not_active Expired - Fee Related
- 2012-06-06 CA CA2838257A patent/CA2838257A1/en not_active Abandoned
- 2012-06-07 AR ARP120102014A patent/AR086852A1/es unknown
-
2013
- 2013-11-28 IL IL229701A patent/IL229701A0/en unknown
- 2013-12-20 ZA ZA2013/09706A patent/ZA201309706B/en unknown
-
2014
- 2014-10-29 HK HK14110839.8A patent/HK1197245A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2718273A1 (en) | 2014-04-16 |
| KR20140037193A (ko) | 2014-03-26 |
| WO2012170536A1 (en) | 2012-12-13 |
| JP2014516077A (ja) | 2014-07-07 |
| ZA201309706B (en) | 2017-04-26 |
| US8815847B2 (en) | 2014-08-26 |
| AU2012268119A1 (en) | 2014-01-23 |
| MX2013014240A (es) | 2014-01-24 |
| IL229701A0 (en) | 2014-01-30 |
| SG195288A1 (en) | 2013-12-30 |
| US20120316156A1 (en) | 2012-12-13 |
| CN103827100A (zh) | 2014-05-28 |
| MY183704A (en) | 2021-03-09 |
| BR112013031484A2 (pt) | 2018-04-24 |
| JP6010614B2 (ja) | 2016-10-19 |
| EA023336B1 (ru) | 2016-05-31 |
| HK1197245A1 (zh) | 2015-01-09 |
| NZ619685A (en) | 2016-01-29 |
| CA2838257A1 (en) | 2012-12-13 |
| AU2012268119B2 (en) | 2017-03-02 |
| EA201391827A1 (ru) | 2014-06-30 |
| CN103827100B (zh) | 2015-08-12 |
| EP2718273A4 (en) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160540A1 (es) | Inhibidores de bromodominios | |
| PH12014502224A1 (en) | Heterobicyclic compounds as beta-lactamase inhibitors | |
| CA2875877C (en) | Syk inhibitors | |
| HK1165954A1 (en) | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
| PE20110845A1 (es) | Nuevos compuestos heterociclicos nitrogenados, preparacion de los mismos y utilizacion de los mismos como medicamentos antibacterianos | |
| AR081638A1 (es) | Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del vih | |
| AR059425A1 (es) | Amidas ciclicas condensadas del acido bencensulfonico, un metodo para su preparacion, composiciones farmaceuticas que las contienen y el empleo de las mismas en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de l-cpt1 | |
| PE20142400A1 (es) | Compuestos novedosos | |
| ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
| AR087995A1 (es) | Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida | |
| AR085668A1 (es) | Terapias combinadas para malignidades hematologicas | |
| EA201490807A1 (ru) | Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1 | |
| EA201490726A1 (ru) | Фармацевтические соединения для применения в терапии инфекции clostridium difficile | |
| AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR083026A1 (es) | Derivados de ciclohexenona y composiciones para el tratamiento del cancer de pulmon | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| PH12015502429A1 (en) | Dicarboxylic acid compound | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| BR112015014433A2 (pt) | compostos tricíclicos | |
| MY165634A (en) | Pyrazole compounds having therapeutic effect on multiple myeloma | |
| PH12014501181A1 (en) | N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics | |
| AR086852A1 (es) | Compuestos de 1,1-dioxido de [1,2,4]tiadiazina para reducir el acido urico serico | |
| AR086865A1 (es) | Metodos y composiciones para el tratamiento del cancer de cerebro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |